TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT07529535

A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors

Cause of deathOther Automatic label, confidence 0.5, unverified. How labels are made.
“Participant recruitment has been stopped because the planned sample size has been reached.”

The sponsor’s own words in the registry.

Life of this trial

202520262027Started2025-06-05Registered2026-04-08Suspended (as of)2026-04-17

Vital statistics

Status
Suspended
Phase
Phase 1
Sponsor
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Sponsor type
Industry
Conditions
Advance Solid Tumors
Interventions
ALK-N001 for Injection
Participants
16
Sites
2
Countries
China

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.